Literature DB >> 26387617

On-demand combinational delivery of curcumin and doxorubicin via a pH-labile micellar nanocarrier.

Haoyu Li1, Man Li1, Chao Chen1, Aiping Fan1, Deling Kong2, Zheng Wang3, Yanjun Zhao4.   

Abstract

The combinational delivery of doxorubicin and curcumin in a physically loaded nanocarrier offers the benefits of enhanced therapeutic efficacy and reduced adverse effects, but this strategy often suffers from the slow drug release followed by delayed onset of pharmacological action. This work reported the hydrazone-linked polymer-curcumin conjugate micelles containing physically loaded doxorubicin to address this problem; the ester-linked conjugate micelles were produced as the control. The pH-labile spherical micelles were less than 100 nm with a loading at 9.3 ± 0.5% (w/w, Curcumin) and 2.5 ± 0.1(w/w, Doxorubicin). Both agents were released at a faster rate in the pH-labile micelles compared to the control. The confocal laser scanning microscopy revealed a time-dependent co-localization of both agents in HepG2 cells. The IC50 of pH-labile conjugate micelles without doxorubicin in HepG2 cells was 27.7 ± 5.3 (μM), whereas the co-loaded micelles was lowered to 10.8 ± 3.4 (μM) (Cur-equivalent dose). The combination index calculation demonstrated a synergistic action of both agents in the co-loading nanocarrier. The current work provided an efficient nanocarrier system to achieve rapid on-demand drug release without onset delay of therapeutic action, which might add value to the clinical translation of the combinational delivery systems.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Combinational delivery; Curcumin; Doxorubicin; Micelle; Stimuli-responsive

Mesh:

Substances:

Year:  2015        PMID: 26387617     DOI: 10.1016/j.ijpharm.2015.09.022

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

1.  Selection of P-Glycoprotein Inhibitor and Formulation of Combinational Nanoformulation Containing Selected Agent Curcumin and DOX for Reversal of Resistance in K562 Cells.

Authors:  Tapan K Dash; V Badireenath Konkimalla
Journal:  Pharm Res       Date:  2017-05-23       Impact factor: 4.200

2.  Co-delivery of curcumin and doxorubicin in PEGylated liposomes favored the antineoplastic C26 murine colon carcinoma microenvironment.

Authors:  Alina Sesarman; Lucia Tefas; Bianca Sylvester; Emilia Licarete; Valentin Rauca; Lavinia Luput; Laura Patras; Sebastian Porav; Manuela Banciu; Alina Porfire
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

Review 3.  Review of Curcumin Physicochemical Targeting Delivery System.

Authors:  Lanmei Li; Xiaomei Zhang; Chao Pi; Hongru Yang; Xiaoli Zheng; Ling Zhao; Yumeng Wei
Journal:  Int J Nanomedicine       Date:  2020-12-07

Review 4.  pH-Responsive Polymer Nanomaterials for Tumor Therapy.

Authors:  Shunli Chu; Xiaolu Shi; Ye Tian; Fengxiang Gao
Journal:  Front Oncol       Date:  2022-03-22       Impact factor: 6.244

Review 5.  Nano-drug co-delivery system of natural active ingredients and chemotherapy drugs for cancer treatment: a review.

Authors:  Bingqian Li; Huili Shao; Lei Gao; Huan Li; Huagang Sheng; Liqiao Zhu
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 6.  The Smart Drug Delivery System and Its Clinical Potential.

Authors:  Dong Liu; Fang Yang; Fei Xiong; Ning Gu
Journal:  Theranostics       Date:  2016-06-07       Impact factor: 11.556

7.  Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach.

Authors:  Lucia Ruxandra Tefas; Bianca Sylvester; Ioan Tomuta; Alina Sesarman; Emilia Licarete; Manuela Banciu; Alina Porfire
Journal:  Drug Des Devel Ther       Date:  2017-05-25       Impact factor: 4.162

8.  Preparation, Physicochemical Properties, and In Vitro Toxicity towards Cancer Cells of Novel Types of Arsonoliposomes.

Authors:  Paraskevi Zagana; Spyridon Mourtas; Anastasia Basta; Sophia G Antimisiaris
Journal:  Pharmaceutics       Date:  2020-04-06       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.